RPS6KA1
ENSG00000117676
Target class
Kinase
Chromosome
1
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- Yes
- Target name
- RPS6KA1
- Gene name
- Ribosomal protein S6 kinase A1
- Gene symbol
- RPS6KA1
- Protein name
- Ribosomal protein S6 kinase alpha-1 (S6K-alpha-1) (EC 2.7.11.1) (90 kDa ribosomal protein S6 kinase 1) (p90-RSK 1) (p90RSK1) (p90S6K) (MAP kinase-activated protein kinase 1a) (MAPK-activated protein kinase 1a) (MAPKAP kinase 1a) (MAPKAPK-1a) (Ribosomal S6 kinase 1) (RSK-1)
- RSK1
- HU-1
- p90Rsk
- MAPKAPK1
- Gene biotype
- Protein coding
- Gene family
- MAPK activated protein kinases|MicroRNA protein coding host genes|Ribosomal protein S6 kinase family
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 180.98
- Tissue specificity (Gini)
- 0.592
- Tissue specificity (tau)
- 0.903
- KEGG gene identifiers
- hsa:6195
- Protein interaction confidence
- 0.866688
- Protein interaction partners
- 32
- R-HSA-198753
- R-HSA-199920
- R-HSA-2559582
- R-HSA-437239
- R-HSA-442742
- R-HSA-444257
- R-HSA-881907
- R-HSA-9856649
- End position
- 26575030
- Start position
- 26529756
- Chromosome
- 1
- Strand
- Forward
- Nucleus. Cytoplasm.
- Cytosol
- Nucleoplasm
- Tissue specificity (tau)
- 0.903421
- Expression inequality (Gini)
- 0.591538
Expression in transcripts per million
- Whole Blood
- 180.98
- Cells - EBV-transformed lymphocytes
- 84.82
- Spleen
- 82.69
- Small Intestine - Terminal Ileum
- 72.65
- Lung
- 65.12
Expression in transcripts per million
- Whole Blood180.98
- Cells - EBV-transformed lymphocytes84.82
- Spleen82.69
- Small Intestine - Terminal Ileum72.65
- Lung65.12
- Thyroid47.37
- Colon - Transverse41.93
- Brain - Cerebellar Hemisphere40.5
- Brain - Cerebellum39.24
- Minor Salivary Gland29.07
- Prostate28.92
- Skin - Sun Exposed (Lower leg)25.08
- Skin - Not Sun Exposed (Suprapubic)22.7
- Stomach21.8
- Kidney - Medulla20.7
- Kidney - Cortex20.23
- Pituitary19.72
- Esophagus - Mucosa19.68
- Adrenal Gland18.05
- Vagina15.1
- Breast - Mammary Tissue13.77
- Brain - Spinal cord (cervical c-1)13.24
- Nerve - Tibial11.37
- Testis10.35
- Pancreas10.23
And 29 more, listed on the interactive page.
- GO:0006355
- GO:0006468
- GO:0007165
- GO:0007268
- GO:0030307
- GO:0032007
- GO:0043066
- GO:0043555
- GO:0045597
- GO:0045944
- GO:2000491
- GO:0005654
- GO:0005829
- GO:0004674
- GO:0004712
- GO:0005515
- GO:0030165
- GO:0051019
Related records
Trials (374)
- "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "
- A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer
- A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
- A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.
- A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
- A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression
- A Phase 1 Study in Participants With Advanced Cancer
- A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
- A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
- A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia
- A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
- A Phase 1/2a Study of K-1728 in Advanced Solid Tumors
- A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer
- A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i
- A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
- A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
- A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
- A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
Drugs (3)
- Palbociclib
- Prexasertib
- TAS0612 p90RSK inhibitor